ObsEva Stock Price

-0.01 (-0.32%)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
ObsEva SA OBSV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.01 -0.32% 3.15 08:29:44
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
3.13 3.15 0.02 - -
Trades Volume Avg Volume 52 Week Range
18 4,140 700,418 1.855 - 7.01
Last Trade Time Type Quantity Stock Price Currency
08:33:14 4 $ 3.15 USD

ObsEva Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 234.38M 74.41M 60.69M $ - $ - -1.67 -2.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

ObsEva News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OBSV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.993.162.87263.01462,8220.165.35%
1 Month2.903.33852.783.00703,4190.258.62%
3 Months3.353.362.532.93805,818-0.20-5.97%
6 Months2.015.551.933.873,572,8411.1456.72%
1 Year5.717.011.8553.642,189,623-2.56-44.83%
3 Years14.4019.401.503.93932,647-11.25-78.13%
5 Years13.2920.351.504.14656,856-10.14-76.3%

ObsEva Description

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The company is focused on providing therapeutic solutions for women between the ages of 15 and 49 who suffer from reproductive health conditions that affect their quality of life, ability to conceive or that complicate pregnancy and the health of newborns. The is developing OBE2109 as a novel, oral gonadotropin-releasing hormone, or GnRH, receptor antagonist, for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.